Safety Study of AZT-04 for Cosmetic Use

NCT ID: NCT03820076

Last Updated: 2020-07-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-17

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Double Blind, Three Cohort, Placebo-controlled Trial to Assess Safety, Tolerance and Induced Bacterial Colony Counts of Three Ascending Doses of AZT-04 in Healthy Adult Volunteers

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-center, prospective, double-blind, three cohort pilot study to assess the tolerability and induced changes in skin microbiome population and diversity of three ascending doses of test article code AZT-04 in normal, healthy subjects.

The study will consist of up to 7 scheduled study visits. There will be three cohorts in this study, each cohort composed of 6 subjects (total number of subjects is at least 18). Each cohort will be treated with both a placebo ointment and an ointment containing different concentrations of the Staphylococcus epidermidis. Approximately 1 ml of placebo ointment and 1 ml of AZT-04 ointment (test product composed of a commensal strain of Staphylococcus epidermidis) will be applied topically to two separate skin sites on the back, each site approximately 8 x 5 cm. Skin microbiome sampling will be performed before application of any test article (i.e., baseline) and each subsequent day for four (4) consecutive days. Samples will be shipped to a laboratory chosen by the Sponsor for analyses

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Study of Three Doses of AZT-04 for Skin Appearance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Double blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dose 1

AZT-04

Group Type EXPERIMENTAL

AZT-04

Intervention Type OTHER

Staphylococcus epidermidis

dose 2

AZT-04

Group Type EXPERIMENTAL

AZT-04

Intervention Type OTHER

Staphylococcus epidermidis

dose 3

AZT-04

Group Type EXPERIMENTAL

AZT-04

Intervention Type OTHER

Staphylococcus epidermidis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZT-04

Staphylococcus epidermidis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fluent in English, willing and able to read, understand, and sign the informed consent form
* Ability to complete the course of the study and comply with instructions
* Makes and Females ages 18-65 years, inclusively, in good general health as deemed by the investigator
* Individuals with Fitzpatrick skin type I, II, III, IV
* Individuals free of any systemic or dermatological disorder including a known history of allergies or other medical conditions which, in the opinion of the investigator, could interfere with the conduct of the study, interpretation of results or increase the risk of adverse reactions.
* Females practicing an acceptable method of birth control

Exclusion Criteria

* individuals with any visible skin disease, skin condition including baseline erythema assessment \> 0.5, or tattoos in the test area
* individuals with abnormal skin pigmentation at the test sites, which might interfere with subsequent evaluations of dermal responsiveness
* individuals with recent prolonged sun or tanning bed exposure in the test area
* individuals with excessive dryness or redness at the sites of application
* individuals with a known hypersensitivity to cosmetic or personal care formulations
* subjects must not have applied any lotions creams, powders, or oils to their backs the morning of the study. Additionally 2 hours must have passed since bathing or showering
* women who are pregnant or nursing
* individuals who have participated on a s study involving the test sites (back) in the previous 14 days
* individuals participating in another clinical study
* individuals with open or healing cuts/incisions abrasions, lesions, pustules, fissures or broken mucosa/skin in the test site
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

RCTs

INDUSTRY

Sponsor Role collaborator

Azitra Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

RCTS, Inc.

Irving, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AZT04-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacokinetics of AZD7295 Capsules
NCT01097408 COMPLETED PHASE1